Sanford Burnham Prebys

CANCER TARGETS AND DRUG DISCOVERY

Currently accepting applications for postdoctoral training in an exciting novel T32 Program

A strength of the Sanford Burnham Prebys Medical Discovery Institute is the discovery of novel cancer targets and therapeutics. The goal of this program is to train the next generation of leaders in cancer target discovery and validation, cancer drug discovery, and biomarker development. This two-year training program will provide the skills needed to execute a successful cancer drug discovery program using novel paradigms and state-of-the-art technologies. The program includes training in scientific entrepreneurship specifically focused on new cancer target and drug discovery. Participants will be provided a solid platform from which to pursue their future cancer-focused careers. In addition to scientific training, participants of this program will take part in a formal curriculum of education and training activities, gaining skills in leadership and management, grant and manuscript writing, and oral presentations.

MENTORS

Postdocs accepted to the program have the opportunity to be mentored by one of the following faculty leaders in their fields:

Peter Adams, PhD: *Targeting mechanisms of aging to prevent liver cancer*

Anindya Bagchi, PhD: *Functional genetics of DNA copy number variation in cancer*

Cosimo Commisso, PhD: *Targeting cancer metabolism in the development of novel therapeutic modalities for Ras-driven tumors*

Nicholas Cosford, PhD: *Chemical biology and drug discovery targeting novel cancer therapeutics*

Max D'Angelo, PhD: *Uncovering the roles of the nuclear transport machinery in cancer*

Ani Deshpande, PhD: *Pathways of immune control hijacked in leukemia and the impact of leukemogenesis on immune evasion*

Brooke Emerling, PhD: *Targeting the metabolic vulnerabilities of cancer cells by phosphoinositide kinase inhibition*

Svasti Haricharan, PhD: *Non-repair roles for DNA damage repair proteins that provide new therapeutic vulnerabilities in cancer cells*

Francesca Marassi, PhD: *Structural biology and functional mechanisms of oncogenic proteins*

Elena Pasquale, PhD: *Tumor suppression and tumor promotion by Eph receptors; Eph receptor targeting strategies*

Ze'ev Ronai, PhD: *Understanding re-wired signaling underlying tumor metastasis and therapy resistance, using biochemical, cell biology, mouse models and human data*

Guy Salvesen, PhD: *Pyroptosis, necroptosis, apoptosis and the control of innate immune responses*

Alexey Terskikh, PhD: *Discovery of interventions/small molecules that reduce biological age to lessen the risk of cancer*

Carl Ware, PhD: *Design and development of immune-therapeutics for cancer, infectious and autoimmune diseases*

Robert Wechsler-Reya, PhD: *Targeting oncogenic pathways in pediatric brain tumors*

Review eligibility requirements, contact us and apply directly at

sbpdiscovery.org/T32